Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Combination therapies combat HIV at cell junctions

By Drug Discovery Trends Editor | February 28, 2014

HIV virus particles produced in an infected cell (green) concentrate at cell junctions with uninfected T-cells (red). Anti-viral therapies can suppress the high concentration of particles at these cell contact sites and prevent development of AIDs, a new study by Yale researchers has shown.A new Yale Univ. study indicates that cell-to-cell transmission of HIV particles contributes to the development of full-blown AIDS and helps predict which anti-retroviral therapies will be most effective at keeping the disease at bay.

The new research reinforces recent findings that a heavy concentration of the virus at the point of contact between cells is crucial to the development of AIDS. The study also suggests that earlier findings that anti-retroviral therapy fails to suppress HIV at cell junctions might be premature. In their new exhaustive analysis of 16 anti-retroviral drugs researchers showed that 13 are effective. Three drugs were effective chiefly reducing viral levels of free-floating HIV, but they fail to suppress HIV spread from cell to cell. However, researchers found that if two of the three that fail are combined they also suppress the spread of HIV, explaining why existing combination anti-viral therapies are effective.

Senior author Walther Mothes, assoc. prof. of microbial pathogenesis, said the effectiveness against highly concentrated HIV should be tested by companies developing more powerful therapies to combat AIDS. The full study may be read in PLOS Pathogens.

Source: Yale Univ.


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50